Larimar Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A novel protein replacement therapy for Friedreich's ataxia demonstrated robust increases in frataxin levels and clinical improvements, surpassing current standards. Regulatory engagement has been collaborative, with a BLA submission and phase III trial planned for mid-2024, supported by strong financials.
-
Breakthrough Therapy designation was achieved, with regulatory alignment on frataxin as a surrogate endpoint and a global Phase III trial set to begin U.S. enrollment in Q2. The focus is on pediatric patients, with a flexible market strategy and promising efficacy data compared to competitors.
-
A novel therapy for Friedreich's ataxia shows promise in raising frataxin levels above the critical threshold, improving clinical outcomes and potentially modifying disease progression. Accelerated approval is being pursued, with a phase III trial and regulatory updates underway.
Fiscal Year 2025
-
Nomlabofusp demonstrated robust increases in frataxin and consistent improvements in key clinical outcomes for Friedreich's ataxia, including mFARS, ADL, fine motor coordination, and fatigue, with a favorable safety profile aside from manageable allergic reactions. Accelerated approval is targeted for 2026.
-
FDA provided written guidance for BLA submission, requiring safety data from 30 participants (10 for one year) mainly at the 50 mg dose, shifting the submission to Q2 2026. Nomlabofusp continues to show promising safety and efficacy signals, with global phase III and open-label studies expanding to broader patient groups.
-
Development is advancing with all patients now on the 50 mg dose and adolescent studies underway. Regulatory discussions support accelerated approval using frataxin as a surrogate endpoint, with a confirmatory study and BLA filing planned for later this year. Cash reserves support operations into 2026.
Fiscal Year 2024
-
Long-term open-label data show nomlabofusp is well tolerated and increases frataxin levels in FA patients, with early trends toward clinical improvement, especially in upper limb function. The program is advancing to higher dosing, pediatric studies, and a global confirmatory trial, with BLA submission targeted for late 2025.